Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study

Table 3 Treatment activity (intention-to-treat/safety population)

Parameter	Patients (n = 123)
Response, n (%)
Complete response	1 (0.8)
Partial response	16 (13.0)
Stable disease	44 (35.8)
Progressive disease	52 (42.3)
Not evaluable	10 (8.1)
Objective response (95% CI)	17 (13.8) (8.3-21.2)
Disease control rate (95% CI)	61 (49.6) (40.5-58.8)
PFS
No. of events, n (%)	117 (95.1)
Median PFS time, wk (95% CI)	12.1 (9.7-17.7)
PFS rate, % (95% CI)
6 wk	72 (64-80)
12 wk	50 (41-59)
18 wk	39 (30-48)
24 wk	25 (17-33)
30 wk	17 (10-23)
36 wk	11 (6-17)
Overall survival
No. of events, n (%)	105 (85.4)
Median survival time, mo (95% CI)	9.5 (7.5-11.6)
Survival rate, % (95% CI)
6 mo	65 (53-73)
12 mo	38 (29-46)
18 mo	25 (18-33)
24 mo	14 (7-20)

PFS: Progression-free survival; CI: confidence interval.